Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_01660 |
| Species: | Homo sapiens |
| Position : | chr12:102818723-103538731 |
| Year: | 2025 |
| Title: | Epigenetic remodeling and 3D chromatin reorganization governed by NKX2-1 drive neuroendocrine prostate cancer |
| Genome Build: | hg38 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | prostate cancer |
| PMID: | 40765356 |
| MONDO: | MONDO:0008315 |
| Tissue: | Prostate |
| Tissue Ontology ID: | UBERON:0002367 |
| Cell Source: | LuCaP93 PDX |
| CVCL ID: | |
| Cell Type: | patient-derived xenograft prostate carcinoma cell |
| Cell Ontology ID: | CL:0000066 |
| Experiment Type: | Chromatin interaction assay, Functional perturbation assay |
| High Throughput Method: | Hi-C, ChIP-seq, RNA-seq |
| Low Throughput Method: | siRNA Knockdown, qRT-PCR, Western blot |
| Target gene : | ASCL1 |
| TF name : | ASCL1 |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| ASCL1 | Notch-mediated HES/HEY network | pid | 48 |
| ASCL1 | Notch | netpath | 76 |
| ASCL1 | Hs_Dopaminergic_Neurogenesis_WP2855_87239 | wikipathways | 19 |
| ASCL1 | Hs_Neural_Crest_Differentiation_WP2064_79263 | wikipathways | 40 |